Next Generation Sequencing Market Introduction and Overview
According to SPER Market Research, the Global Next Generation Sequencing Market is estimated to reach USD 129.58 billion by 2033 with a CAGR of 22.44%.
The report includes an in-depth analysis of the Global Next Generation Sequencing Market, including market size and trends, product mix, distribution channels, and supplier analysis. Next-generation sequencing" refers to the wide spectrum of DNA sequencing methods used in genomic research. The international hunt for immunisations and test kits has received backing from a large number of biotechnology and pharmaceutical companies. These methods are far quicker and less expensive than the Sanger DNA and RNA sequencing that was previously utilised, which has revolutionised research in genomics and molecular biology.
- Advancements in NGS Technology: Next-generation sequencing has witnessed significant technological advancements in recent years, leading to increased sequencing capacity, improved accuracy, and reduced costs. These advancements have made NGS more accessible and affordable for a wider range of applications, driving its adoption across various sectors.
- June 2023: Together with Geneyx - an AI platform, Oxford Nanopore Technologies Plc, a developer of nanopore sequencing technology, unveiled a scalable software solution for enhancing next-generation nanopore sequencing technology. This will provide hospitals and health centres with analytical data related to genome sequencing, including genetic labs.
Market Opportunities and Challenges
One of the significant market opportunities in the global Next Generation Sequencing (NGS) market is the growing demand for precision medicine. NGS technologies play a crucial role in advancing personalized medicine by enabling the identification of genomic variants associated with diseases and tailoring treatments based on an individual's genetic makeup. The ability of NGS to provide comprehensive genomic information quickly and cost-effectively positions it as a key tool in the development of targeted therapies and improving patient outcomes.
NGS generates massive amounts of genomic data, and effectively managing, analysing, and extracting meaningful insights from this data remains a challenge. The analysis requires sophisticated bioinformatics tools, computational resources, and expertise. The shortage of skilled bioinformaticians and the need for continuous advancements in data analysis algorithms pose challenges in fully harnessing the potential of NGS technology and translating genomic data into actionable clinical insights. Overcoming this challenge is crucial for the widespread adoption and integration of NGS into routine clinical practice.
Market Competitive Landscape
The market for next-generation sequencing is quite fragmented, with a number of major global competitors. The major players are utilising a variety of growth tactics to improve their market presence, including mergers, acquisitions, partnerships, agreements, collaborations, new product launches, and geographic expansions. Some of the key players in the market are Agilent Technologies Inc., BGI, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Genomatix GmbH, Illumina Inc., Macrogen Inc., Oxford Nanopore Technologies, Pacific Biosciences of California Inc., PierianDx Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Others.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2033 |
| Base year considered | 2022 |
| Forecast period | 2023-2033 |
| Segments covered | By Product Type, By Type of Sequencing Technology, By Application, By End-User
|
| Regions covered | Asia-Pacific, Europe, Middle East and Africa, North America, Latin America
|
| Companies Covered | Agilent Technologies Inc., BGI, Bio-Rad Laboratories Inc., CD Genomics, DNASTAR Inc., Eurofins GATC Biotech GmbH, F. Hoffmann-La Roche AG, Genomatix GmbH, Illumina Inc., Intrexon Bioinformatics Germany GmbH (Precigen Inc.), Macrogen Inc., Oxford Nanopore Technologies, Pacific Biosciences of California Inc., PerkinElmer Inc., Pillar Biosciences Inc., PierianDx Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Others
|
COVID-19 Impact on Global Next Generation Sequencing Market
During the COVID-19 pandemic, there was an increased demand for NGS technologies that could facilitate remote data analysis and interpretation, driven by the adoption of telemedicine and remote healthcare services. Governments worldwide recognized the importance of genomics and NGS technology in pandemic response and provided increased funding and support. The pandemic also prompted collaborations and partnerships among NGS companies, research institutions, and healthcare organizations, leading to knowledge-sharing and market consolidation. The significance of genomics and personalized medicine highlighted during the pandemic is expected to drive long-term growth in the NGS market as awareness and interest in genomics increase.
Key Target Audience:
- Healthcare Providers
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutions
- Diagnostic Laboratories
- Bioinformatics Companies
- Government Agencies and Regulatory Bodies
- Investors and Venture Capitalists
- Patients and Patient Advocacy Groups
- Insurance Companies and Payers
- Genomic Data and Biobanking Organizations
Our in-depth analysis of the Next Generation Sequencing Market includes the following segments:
|
By Product Type:
|
Instruments
Reagents and Consumables
Products & Services
Software
|
|
By Type of Sequencing Technology:
|
CHIP Sequencing
De Novo Sequencing
Methyl Sequencing
RNA Sequencing
Targeted Resequencing
Whole Exome Sequencing
Whole Genome Sequencing
|
|
By Application:
|
Agriculture and Animal Research
Diagnostics
Drug Discovery
Genetic Screening
Other Applications
|
|
By End-User:
|
Academics and Research Centres
Contract Research Organizations
Hospitals and Healthcare Institutions
|
Key Topics Covered in the Report:
- Global Next Generation Sequencing Market Size (FY’2023-FY’2033)
- Description of Global Next Generation Sequencing Market
- Segmentation of Global Next Generation Sequencing Market By Product Type (Reagents and Consumables, Software, Products & Services, Instruments)
- Segmentation of Global Next Generation Sequencing Market By Type of Sequencing Technology (CHIP Sequencing, De Novo Sequencing, Methyl Sequencing, RNA Sequencing, Targeted Resequencing, Whole Exome Sequencing, Whole Genome Sequencing)
- Segmentation of Global Next Generation Sequencing Market By Application (Agriculture and Animal Research, Diagnostics, Drug Discovery, Genetic Screening, Personalized Medicine, Other Applications)
- Segmentation of Global Next Generation Sequencing Market By End-User (Academics and Research Centres, Contract Research Organizations, Hospitals and Healthcare Institutions, Pharmaceutical and Biotechnology Companies, Others)
- Statistical Snap of Global Next Generation Sequencing Market
- Expansion Analysis of Global Next Generation Sequencing Market
- Problems and Obstacles in Global Next Generation Sequencing Market
- Competitive Landscape in the Global Next Generation Sequencing Market
- Impact of COVID-19 and Demonetization on Global Next Generation Sequencing Market
- Details on Current Investment in Global Next Generation Sequencing Market
- Competitive Analysis of Global Next Generation Sequencing Market
- Prominent Players in the Global Next Generation Sequencing Market
- SWOT Analysis of Global Next Generation Sequencing Market
- Global Next Generation Sequencing Market Future Outlook and Projections (FY’2023-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Next Generation Sequencing Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Next Generation Sequencing Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Next Generation Sequencing Market
7. Global Next Generation Sequencing Market, By Product Type (USD Million)
7.1. Global Next Generation Sequencing Market Value Share and Forecast, By Product Type, 2023-2033
7.2. Instruments
7.3. Reagents and Consumables
7.4. Products & Services
7.5. Software
8. Global Next Generation Sequencing Market, By Type of Sequencing Technology (USD Million)
8.1. Global Next Generation Sequencing Market Value Share and Forecast, By Type of Sequencing Technology, 2023-2033
8.2. CHIP Sequencing
8.3. De Novo Sequencing
8.4. Methyl Sequencing
8.5. RNA Sequencing
8.6. Targeted Resequencing
8.7. Whole Exome Sequencing
8.8. Whole Genome Sequencing
9. Global Next Generation Sequencing Market, By Application (USD Million)
9.1. Global Next Generation Sequencing Market Value Share and Forecast, By Application, 2023-2033
9.2. Agriculture and Animal Research
9.3. Diagnostics
9.4. Drug Discovery
9.5. Genetic Screening
9.6. Personalized Medicine
9.7. Other Applications
10. Global Next Generation Sequencing Market, By End-User (USD Million)
10.1. Global Next Generation Sequencing Market Value Share and Forecast, By End-User, 2023-2033
10.2. Academics and Research Centres
10.3. Contract Research Organizations
10.4. Hospitals and Healthcare Institutions
10.5. Pharmaceutical and Biotechnology Companies
10.6. Others
11. Global Next Generation Sequencing Market Forecast, 2019-2033 (USD Million)
11.1. Global Next Generation Sequencing Market Size and Market Share
12. Global Next Generation Sequencing Market, By Product Type, 2019-2033 (USD Million)
12.1. Global Next Generation Sequencing Market Size and Market Share By Product Type (2019-2026)
12.2. Global Next Generation Sequencing Market Size and Market Share By Product Type (2027-2033)
13. Global Next Generation Sequencing Market, By Type of Sequencing Technology, 2019-2033 (USD Million)
13.1. Global Next Generation Sequencing Market Size and Market Share By Type of Sequencing Technology (2019-2026)
13.2. Global Next Generation Sequencing Market Size and Market Share By Type of Sequencing Technology (2027-2033)
14. Global Next Generation Sequencing Market, By Application, 2019-2033 (USD Million)
14.1. Global Next Generation Sequencing Market Size and Market Share By Application (2019-2026)
14.2. Global Next Generation Sequencing Market Size and Market Share By Application (2027-2033)
15. Global Next Generation Sequencing Market, By End-User, 2019-2033 (USD Million)
15.1. Global Next Generation Sequencing Market Size and Market Share By End-User (2019-2026)
15.2. Global Next Generation Sequencing Market Size and Market Share By End-User (2027-2033)
16. Global Next Generation Sequencing Market, By Region, 2019-2033 (USD Million)
16.1. Global Next Generation Sequencing Market Size and Market Share By Region (2019-2026)
16.2. Global Next Generation Sequencing Market Size and Market Share By Region (2027-2033)
16.3. Asia-Pacific
16.3.1. Australia
16.3.2. China
16.3.3. India
16.3.4. Japan
16.3.5. South Korea
16.3.6. Rest of Asia-Pacific
16.4. Europe
16.4.1. France
16.4.2. Germany
16.4.3. Italy
16.4.4. Spain
16.4.5. United Kingdom
16.4.6. Rest of Europe
16.5. Middle East and Africa
16.5.1. Kingdom of Saudi Arabia
16.5.2. United Arab Emirates
16.5.3. Rest of Middle East & Africa
16.6. North America
16.6.1. Canada
16.6.2. Mexico
16.6.3. United States
16.7. Latin America
16.7.1. Argentina
16.7.2. Brazil
16.7.3. Rest of Latin America
17. Company Profile
17.1. Agilent Technologies Inc.
17.1.1. Company details
17.1.2. Financial outlook
17.1.3. Product summary
17.1.4. Recent developments
17.2. BGI
17.2.1. Company details
17.2.2. Financial outlook
17.2.3. Product summary
17.2.4. Recent developments
17.3. Bio-Rad Laboratories Inc.
17.3.1. Company details
17.3.2. Financial outlook
17.3.3. Product summary
17.3.4. Recent developments
17.4. CD Genomics
17.4.1. Company details
17.4.2. Financial outlook
17.4.3. Product summary
17.4.4. Recent developments
17.5. DNASTAR Inc.
17.5.1. Company details
17.5.2. Financial outlook
17.5.3. Product summary
17.5.4. Recent developments
17.6. Eurofins GATC Biotech GmbH
17.6.1. Company details
17.6.2. Financial outlook
17.6.3. Product summary
17.6.4. Recent developments
17.7. F. Hoffmann-La Roche AG
17.7.1. Company details
17.7.2. Financial outlook
17.7.3. Product summary
17.7.4. Recent developments
17.8. Genomatix GmbH
17.8.1. Company details
17.8.2. Financial outlook
17.8.3. Product summary
17.8.4. Recent developments
17.9. Illumina Inc.
17.9.1. Company details
17.9.2. Financial outlook
17.9.3. Product summary
17.9.4. Recent developments
17.10. Intrexon Bioinformatics Germany GmbH (Precigen Inc.)
17.10.1. Company details
17.10.2. Financial outlook
17.10.3. Product summary
17.10.4. Recent developments
17.11. Macrogen Inc.
17.11.1. Company details
17.11.2. Financial outlook
17.11.3. Product summary
17.11.4. Recent developments
17.12. Oxford Nanopore Technologies
17.12.1. Company details
17.12.2. Financial outlook
17.12.3. Product summary
17.12.4. Recent developments
17.13. Pacific Biosciences of California Inc.
17.13.1. Company details
17.13.2. Financial outlook
17.13.3. Product summary
17.13.4. Recent developments
17.14. PerkinElmer Inc.
17.14.1. Company details
17.14.2. Financial outlook
17.14.3. Product summary
17.14.4. Recent developments
17.15. Pillar Biosciences Inc.
17.15.1. Company details
17.15.2. Financial outlook
17.15.3. Product summary
17.15.4. Recent developments
17.16. PierianDx Inc.
17.16.1. Company details
17.16.2. Financial outlook
17.16.3. Product summary
17.16.4. Recent developments
17.17. QIAGEN N.V.
17.17.1. Company details
17.17.2. Financial outlook
17.17.3. Product summary
17.17.4. Recent developments
17.18. Thermo Fisher Scientific Inc.
17.18.1. Company details
17.18.2. Financial outlook
17.18.3. Product summary
17.18.4. Recent developments
17.19. Others
18. List of Abbreviations
19. Reference Links
20. Conclusion
21. Research Scope